ESC: Eli Lilly, Boehringer’s Jardiance cuts CV events by 25% in Farxiga-matching heart failure trial
AstraZeneca put the rest of the SGLT2 inhibitor class on notice when its Farxiga scored an FDA heart failure nod in patients with or without diabetes. One of its competitors, Eli Lilly and Boehringer Ingelheim’s Jardiance, is fast on Farxiga’s heels, though, and it’s ready to bring its pivotal trial win in front of physicians. Jardiance, added… Read More »